COVID-19 infection and myocarditis after surgical left ventricle reconstruction in patient with hypertrophic cardiomyopathy
Abstract
It has now been shown that severe
acute respiratory syndrome coronavirus 2 (SARS-CoV-2) causing a new COVID-19 infection, can
penetrate the myocardium and have both direct damaging and toxic effects. The
main cardiac manifestations of this disease are fulminant myocarditis, atrial
and ventricular arrhythmias, and heart failure. Cardiac arrhythmias are common
complication not only in adult patients, but also in children. In this paper,
we present a clinical case of the young female patient who successfully
underwent operation because of a submitral (diffuse-generalized) form of HCM, with a long event-free postoperative
course, and with the rapid cardiac dysfunction, syncopes and cardiac
arrhythmias after COVID-19 infection. Syncopes were caused by self-terminating
short runs of ventricular tachycardia that did not trigger ICD shock. After the
medical treatment of myocarditis, she
has a clinical improvement and further favorable postoperative period.
Keywords:hypertrophic cardiomyopathy (HCM); submitral HCM; MYH7; coronavirus; myocarditis; sudden cardiac death
Funding. The study had no
sponsor support.
Conflict of
interest. The authors declare no conflict of interest.
For citation: Dzemeshkevich
S.L., Motreva A.P., Мартьянова Yu.B., Kalmykova O.V., Dombrovskaya A.V.,
Nikituk T.G., Podolyak D.G., Polyak M.E., Zaklyazminskaya E.V. COVID-19
infection and myocarditis after surgical left ventricle reconstruction in
patient with hypertrophic cardiomyopathy. Clinical and Experimental Surgery.
Petrovsky Journal. 2022; 10 (2): 13–8.
DOI: https://doi.org/10.33029/2308-1198-2022-10-2-13-18 (in
Russian)
References
1. Guzik T.J., Mohiddin S.A., Dimarco A., Patel V., Savvatis K., Marelli-Berg F.M., et al. COVID-19 and the cardiovascular system: implications for risk assessment, diagnosis, and treatment options. Cardiovasc Res. 2020; 116 (10): 1666–87. DOI: https://doi.org/10.1093/cvr/cvaa106
2. Sergienko I.V., Rezinkina P.K. New coronavirus infection COVID-19 and cardiovascular diseases. Therapy features. Ateroskleroz i dislipidemii [Atherosclerosis and Dyslipidemia]. 2021; 2 (43): 5–23. (in Russian)
3. Babaev M.A., Petrushin M.A., Dubrovin I.A., et al. Acute myocardial damage with coronavirus disease 2019 (COVID-19) (case study). Clinical and Experimental Surgery. Petrovsky Journal. 2020; 8 (3): 87–94. (in Russian)
4. Blagova O.V., Sedov A.V., Savina P.O., et al. Obstructive hypertrophic cardiomyopathy in association with chronic exudative pericarditis and COVID-19. Clinical and Experimental Surgery. Petrovsky Journal. 2020; 8 (3): 95–109. (in Russian)
5. Kohli U., Meinert E., Chong G., Tesher M., Jani P. Fulminant myocarditis and atrial fibrillation in child with acute COVID-19. J Electrocardiol. 2020; Oct 18: S0022-0736(20)30571-9. DOI: https://doi.org/10.1016/j.jelectrocard.2020.10.004
6. Maron B.J., Shen W.-K., Link M.S., et al. Efficacy of implantable cardioverter-defibrillator for prevention of sudden death in patients with hypertrophic cardiomyopathy. N Engl J Med. 2000; 342: 365–73.
7. Ryzhkova O., Kardymon O., Prokhorchuk E., Konovalov F., Maslennikov A., Stepanov V., et al. Guidelinies for interpretation of the human DNA sequencing data by massive parallele sequencing methods (MPS) (ed. 2018, version 2). Meditsinskaya genetika [Medical Genetics]. 2019; 18 (2): 3–23. DOI: https://doi.org/10.25557/2073-7998.2019.02.3-23 (in Russian)
8. Trivedi A., Knight B.P. ICD Therapy for primary prevention in hypertrophic cardiomyopathy. Arrhythm Electrophysiol Rev. 2016; 5 (3): 188–98.
9. Ommen S.R., Mital S., Burke M.A., Day S.M., Deswal A., Elliott P., et al. 2020 AHA/ACC guideline for the diagnosis and treatment of patients with hypertrophic cardiomyopathy: a report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation. 2020; 142 (25): e558–631. DOI: https://doi.org/10.1161/CIR.0000000000000937
10. Dzemeshkevich S.L., Motreva A.P., Kalmykova O.V., et al. Hypertrophic cardiomyopathy in young: phenotype, genotype and treatment approaches. Clinical and Experimental Surgery. Petrovsky Journal. 2019; 7 (3): 54–62. (in Russian)